The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Predicting and preventing therapy-related myeloid neoplasms
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the findings of an ongoing study on predicting and preventing therapy-related myeloid neoplasms in patients undergoing chemotherapy or radiation. Dr Desai highlights predictors of pre-malignant mutations in patients with prostate cancer receiving PSMA-targeted radiation therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
